|
|
Vaccine Comparison
|
Actinobacillus pleuropneumoniae HS93Tox-/pIG-T1K vectored vaccine |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004607
- Type: Recombinant vector vaccine
- Status: Research
- Host Species as Laboratory Animal Model: Mice
- Vector:
- Preparation: The HS93Tox- mutant of the serovar 7 strain of Actinobacillus pleuropneumoniae lacks the genes encoding the toxin ApxA and the post-translational activating protein ApxC, but still has genes required for secretion, making it a good vector. A plasmid vector was created to express the ApxA gene inside the HS93Tox- mutant of A. pleuropneumoniae, so that the bacterium acts as a vector for its own natural toxin (Prideaux et al., 1998).
- Immunization Route: Intramuscular injection (i.m.)
- Virulence: Because the toxin has been attenuated, this greatly decreases the potential virulence of the vaccine.
- Description: The HS93Tox-/pIG-T1K vector strain, using an Actinobacillus pleuropneumoniae to express the AxpA gene, was shown to protect mice against Actinobacillus pleuropneumoniae challenges (Prideaux et al., 1998). ApxA gene encodes an A. pleuropneumoniae structural toxin (Prideaux et al., 1998).
|
| References |
Prideaux et al., 1998: Prideaux CT, Pierce L, Krywult J, Hodgson AL. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Current microbiology. 1998; 37(5); 324-332. [PubMed: 9767712].
|
|
HS93Tox-/pIG-T1K |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004637
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- apxIA
gene engineering:
- Type: Recombinant vector construction
- Description: HS93Tox-/pIG-T1K, expresses the Apx structural protein in a non-activated form (Prideaux et al., 1998).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: HS93Tox-/pIG-T1K, expresses the Apx structural protein in a non-activated form (Prideaux et al., 1998).
- Immunization Route: Intramuscular injection (i.m.)
|
| References |
Prideaux et al., 1998: Prideaux CT, Pierce L, Krywult J, Hodgson AL. Protection of mice against challenge with homologous and heterologous serovars of Actinobacillus pleuropneumoniae after live vaccination. Current microbiology. 1998; 37(5); 324-332. [PubMed: 9767712].
|
|
rS.C-APP-ApxI/ApxII |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004785
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- apxIA
gene engineering:
- Type: Recombinant vector construction
- Description: S. cerevisiae expressing either ApxI or ApxII (Shin et al., 2013).
- Detailed Gene Information: Click Here.
- apxIIA
gene engineering:
- Type: Recombinant vector construction
- Description: S. cerevisiae expressing either ApxI or ApxII (Shin et al., 2013).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: The surface-displayed ApxIIA#5 expressing S. cerevisiae and the ApxIA expressing S. cerevisiae (Shin et al., 2013).
- Immunization Route: Oral immunization
|
| References |
Shin et al., 2013: Shin MK, Kang ML, Jung MH, Cha SB, Lee WJ, Kim JM, Kim DH, Yoo HS. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs. Veterinary immunology and immunopathology. 2013; 151(1-2); 132-139. [PubMed: 23206402].
|
|
rS.C-APP-ApxIIA |
| Vaccine Information |
- Vaccine Ontology ID: VO_0004786
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Baboon
- apxIIA
gene engineering:
- Type: Recombinant vector construction
- Description: A neutralizing epitope fragment of ApxIIA toxin was expressed on the cell surface of Saccharomyces cerevisiae (Kim et al., 2010).
- Detailed Gene Information: Click Here.
- Vector:
- Preparation: (Kim et al., 2010) A neutralizing epitope fragment of ApxIIA toxin was expressed and immobilized on the cell surface of Saccharomyces cerevisiae for efficient vaccine development.
- Immunization Route: Oral vaccination
|
| References |
Kim et al., 2010: Kim JM, Jung DI, Eom YJ, Park SM, Yoo HS, Jang YS, Yang MS, Kim DH. Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae. Bioscience, biotechnology, and biochemistry. 2010; 74(7); 1362-1367. [PubMed: 20622458].
|
|
